FUSILEV Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6500829 | ACROTECH | Substantially pure diastereoisomers of tetrahydrofolate derivatives |
Mar, 2022
(1 year, 6 months ago) | |
Fusilev is owned by Acrotech.
Fusilev contains Levoleucovorin Calcium.
Fusilev has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Fusilev are:
- US6500829
Fusilev was authorised for market use on 07 March, 2008.
Fusilev is available in powder;intravenous, solution;intravenous dosage forms.
The generics of Fusilev are possible to be released after 07 March, 2022.
Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient
Market Authorisation Date: 07 March, 2008
Treatment: NA
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
How can I launch a generic of FUSILEV before it's drug patent expiration?
More Information on Dosage
FUSILEV family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic